Viz.ai partners with UCSF to commercialize AI algorithms for cardiovascular disease detection
Viz.ai, a frontrunner in artificial intelligence (AI) powered disease detection and intelligent care coordination, has inked an exclusive agreement with the University of California, San ... Read More
Merck launches Phase 3 CORALreef program for PCSK9 inhibitor MK-0616
Pharmaceutical giant Merck has announced the initiation of its groundbreaking Phase 3 clinical program, CORALreef, focusing on MK-0616—a novel, oral proprotein convertase subtilisin/kexin type 9 ... Read More
XyloCor reveals promising 12-month data from Phase 2 Trial of XC001
XyloCor Therapeutics, a clinical-stage biopharmaceutical company focusing on novel gene therapies for cardiovascular diseases, has revealed encouraging 12-month data from the Phase 2 section of ... Read More
FDA approves Cardio Flow Design’s iTFlow for enhanced cardiovascular diagnosis
The US Food and Drug Administration (FDA) has granted approval for iTFlow, a software solution developed by Cardio Flow Design Inc. (Japan), that improves the ... Read More
OMRON Healthcare to launch manufacturing operations in Origins by Mahindra, Chennai
OMRON Healthcare, a Japanese manufacturer and distributor of blood pressure monitors and cardiovascular disease prevention services, has announced its plans to launch operations in Chennai, ... Read More
Johnson & Johnson to purchase heart pump maker Abiomed for $16.6bn
Johnson & Johnson (J&J) has agreed to acquire Abiomed, a NASDAQ-listed cardiovascular medical technology provider, in an all-cash deal valued at approximately $16.6 billion. The ... Read More
Novo Nordisk to acquire cardio-renal disease company Corvidia Therapeutics
Novo Nordisk acquisition of Corvidia : Danish pharma company Novo Nordisk has agreed to acquire Corvidia Therapeutics from life sciences venture capital firm Sofinnova Partners ... Read More
Lilly bags Trulicity FDA approval for reducing CV risk in type 2 diabetes patients
Trulicity FDA approval : Eli Lilly and Company (Lilly) has secured approval from the US Food and Drug Administration (FDA) for Trulicity (dulaglutide) to reduce ... Read More
Amarin bags Vascepa FDA approval for reducing cardiovascular risk
Vascepa FDA approval : New Jersey-based Amarin has secured approval from the US Food and Drug Administration (FDA) for a new indication and label expansion ... Read More
Novartis to acquire The Medicines Company for $9.7bn with eye on inclisiran
Novartis acquisition of The Medicines Company : Swiss drugmaker Novartis signed a deal worth $9.7 billion to acquire US biopharma company The Medicines Company, as ... Read More